Biodexa Pharmaceuticals PLC (BDRX) — SEC Filings

Overview

Biodexa Pharmaceuticals PLC (BDRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 3, 2025: Biodexa Pharmaceuticals PLC announced on November 3, 2025, that it has received approval for its Clinical Trial Application (CTA) in Europe for the Phase 3 Serenta clinical trial. This approval allows the company to proceed with its pivotal trial for Serenta, a key step in its drug development proce

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 49 neutral. The dominant filing sentiment for Biodexa Pharmaceuticals PLC is neutral.

Filing Type Overview

Biodexa Pharmaceuticals PLC (BDRX) has filed 43 6-K, 1 20-F, 4 SC 13G/A, 2 SC 13G with the SEC between Jun 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Dec 18, 2025
• Biodexa Pharma Gets European CTA Approval for Phase 3 Serenta Trial — 6-K · Nov 3, 2025 Risk: medium
  Biodexa Pharmaceuticals PLC announced on November 3, 2025, that it has received approval for its Clinical Trial Application (CTA) in Europe for the Phase 3 Sere
• Biodexa Pharmaceuticals Plc Files 6-K Report — 6-K · Sep 12, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on September 12, 2025, reporting for the period ending June 30, 2025. The company, formerly known as Midatech Pharm
• Biodexa Pharmaceuticals Files 6-K — 6-K · Aug 18, 2025 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 18, 2025. The company, based in Cardiff, United Kingdom, is a pharmaceutic
• Biodexa Pharmaceuticals Files July 2025 6-K Report — 6-K · Jul 31, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on July 31, 2025, reporting for the month of July 2025. The company, formerly known as Midatech Pharma Plc, is base
• Biodexa Pharmaceuticals Files July 2025 6-K Report — 6-K · Jul 15, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on July 15, 2025, reporting for the month of July 2025. The company, formerly known as Midatech Pharma Plc, is base
• Biodexa Pharmaceuticals PLC Holds Annual General Meeting — 6-K · Jun 27, 2025 Risk: low
  Biodexa Pharmaceuticals PLC held its Annual General Meeting on June 27, 2025. The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Ki
• Biodexa Pharmaceuticals PLC Files 6-K — 6-K · Jun 13, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on June 13, 2025, reporting on a general meeting of shareholders held on June 11, 2025. The filing indicates that t
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Jun 11, 2025 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on June 11, 2025. The filing is a report of a foreign private issuer and indicates t
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Jun 4, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on June 4, 2025, to report information for the month of June 2025. The company, formerly known as Midatech Pharma P
• Biodexa Pharmaceuticals Files May 2025 6-K Report — 6-K · May 30, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on May 30, 2025, reporting for the month of May 2025. The company, formerly known as Midatech Pharma Plc, is a fore
• Biodexa Pharmaceuticals Files 2024 Annual Report — 6-K · May 23, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed its annual report for the year ended December 31, 2024, on May 23, 2025. The company, formerly known as Midatech Pharma Plc, i
• Biodexa Pharmaceuticals Plc Files 6-K — 6-K · May 22, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on May 22, 2025, to report information as a foreign private issuer. The filing indicates the company's principal ex
• Biodexa Pharmaceuticals Files 6-K — 6-K · May 22, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on May 22, 2025, to report information for the month of May 2025. The filing indicates that the company, formerly k
• Biodexa Pharmaceuticals PLC Enters Letter Agreements — 6-K · May 15, 2025 Risk: low
  On May 15, 2025, Biodexa Pharmaceuticals PLC entered into letter agreements with certain parties. The company, formerly known as Midatech Pharma Plc, is a pharm
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · May 12, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on May 12, 2025, reporting information for the month of May 2025. The filing indicates that the company, formerly k
• Biodexa Pharmaceuticals PLC Announces General Meeting Results — 6-K · May 2, 2025 Risk: low
  Biodexa Pharmaceuticals PLC held a General Meeting on May 2, 2025, where it announced results. The company, formerly known as Midatech Pharma Plc, is based in C
• Biodexa Pharmaceuticals Files 6-K, Furnishes Exhibit 99.1 — 6-K · Apr 17, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on April 17, 2025, to report information as a foreign private issuer. The filing indicates that the company will fi
• Biodexa Pharmaceuticals Plc Files 2024 Annual Report — 20-F · Apr 11, 2025 Risk: medium
  Biodexa Pharmaceuticals Plc filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, formerly known as Midatech Pharma Pl
• Biodexa Pharmaceuticals Files Routine 6-K Report — 6-K · Mar 10, 2025 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on March 10, 2025. This report is for the month of March 2025 and indicates the comp
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Mar 6, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on March 6, 2025, to report information for the month of March 2025. The company, formerly known as Midatech Pharma
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Feb 24, 2025 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on February 24, 2025, reporting for the month of February 2025. The company, formerly known as Midatech Pharma Plc,
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Feb 13, 2025 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on February 13, 2025. The filing is a report of a foreign private issuer for the mon
• Biodexa Pharmaceuticals Files Form 6-K — 6-K · Feb 10, 2025 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on February 10, 2025, to report information for the month of February 2025. The company, formerly known as Midatech
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Jan 22, 2025 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on January 22, 2025. The filing is a report of a foreign private issuer and indicate
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Jan 17, 2025 Risk: low
  Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on January 17, 2025. The filing is a report of a foreign private issuer for the mont
• Biodexa Pharmaceuticals Plc Files 6-K Report — 6-K · Dec 27, 2024 Risk: low
  Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on December 27, 2024. The filing is a report of a foreign private issuer for the mon
• Biodexa Pharmaceuticals Plc Files December 2024 6-K Report — 6-K · Dec 4, 2024 Risk: low
  Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on December 4, 2024. This report is for the month of December 2024 and indicates the
• SC 13G/A Filing — SC 13G/A · Nov 20, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Biodexa Pharma Complies with Nasdaq Bid Price Rule — 6-K · Nov 12, 2024 Risk: low
  Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on November 12, 2024, to report compliance with the Nasdaq minimum bid price require
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Nov 7, 2024 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on November 7, 2024. This report is for the month of November 2024 and indicates the
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• Biodexa Pharmaceuticals Appoints New Auditor — 6-K · Nov 1, 2024 Risk: low
  Biodexa Pharmaceuticals Plc announced on November 1, 2024, the appointment of PKF Littlejohn LLP as its new auditor, replacing BDO LLP. This change is effective
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Oct 15, 2024 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on October 15, 2024. The filing is a report of a foreign private issuer and indicates the company files annual repo
• Biodexa Pharmaceuticals Files 6-K — 6-K · Oct 4, 2024 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on October 4, 2024, to report information as a foreign private issuer. The filing indicates that the company will f
• Biodexa Pharmaceuticals Plc Files 6-K with Financial Data — 6-K · Sep 26, 2024 Risk: low
  Biodexa Pharmaceuticals Plc filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the six months ended June 30, 2024, a
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Sep 19, 2024 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 19, 2024. The company, located at 1 Caspian Point, Caspian Way, Cardiff
• Biodexa Pharmaceuticals Files 6-K Report — 6-K · Sep 16, 2024 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 16, 2024. The company, incorporated in X0 with its principal executive
• Biodexa Pharmaceuticals Files Form 6-K — 6-K · Aug 30, 2024 Risk: low
  Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 30, 2024. The company, based in Cardiff, United Kingdom, operates in the P
• SC 13G Filing — SC 13G · Aug 8, 2024
• Biodexa Sells Subsidiary for £1 — 6-K · Jul 23, 2024 Risk: medium
  Biodexa Pharmaceuticals Plc announced on July 23, 2024, that it has entered into a binding agreement to sell its entire issued share capital in its subsidiary,
• SC 13G Filing — SC 13G · Jul 23, 2024
• Biodexa Pharmaceuticals Raises $10M in Direct Offering — 6-K · Jul 19, 2024 Risk: medium
  Biodexa Pharmaceuticals PLC announced on July 18, 2024, that it has entered into agreements for a registered direct offering and a concurrent private placement.
• Biodexa Pharmaceuticals Plc Files 6-K Report — 6-K · Jul 16, 2024 Risk: low
  Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on July 16, 2024. The filing indicates that the company, based in Cardiff, United Ki
• Biodexa Pharmaceuticals PLC: CSO/CMO Departs — 6-K · Jul 5, 2024 Risk: medium
  Biodexa Pharmaceuticals PLC announced the departure of Dmitry Zamoryakhin as Chief Scientific Officer and Chief Medical Officer, effective July 4, 2024. The com
• Biodexa Pharmaceuticals Files Form 6-K — 6-K · Jul 2, 2024 Risk: low
  Biodexa Pharmaceuticals Plc filed a Form 6-K on July 2, 2024, to report information for the month of July 2024. The filing indicates that the company is a forei
• Biodexa Pharmaceuticals Files Routine 6-K — 6-K · Jun 24, 2024 Risk: low
  Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on June 24, 2024. This report is for the month of June 2024 and indicates the compan
• Biodexa Pharmaceuticals PLC Files 6-K, Incorporates Exhibits — 6-K · Jun 13, 2024 Risk: low
  Biodexa Pharmaceuticals PLC filed a Form 6-K on June 13, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (F

Risk Profile

Risk Assessment: Of BDRX's 43 recent filings, 0 were flagged as high-risk, 5 as medium-risk, and 38 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Dmitry Zamoryakhin

Top Tags

foreign-private-issuer (21) · reporting (12) · sec-filing (10) · regulatory-filing (9) · pharmaceuticals (8) · company-update (4) · foreign-issuer (4) · 6-K (4) · disclosure (4) · routine-filing (2)

Key Numbers

• Fiscal Year End: 2024-12-31 — The period covered by the annual report.
• Filing Date: 2025-04-11 — The date the 20-F was submitted to the SEC.
• Reporting Period End Date: 2024-06-30 — Financial data pertains to this date and prior periods.
• Prior Year End Date: 2023-12-31 — Comparative financial data is provided for this date.
• SEC File Number: 001-37652 — Identifies the company's filing with the SEC.
• Commission File Number: 001-37652 — Identifies the company's filing with the SEC.
• Form S-8 File Number: 333-209365 — Registration statement for employee stock plans.
• Form F-3 File Number: 333-267932 — Registration statement for offerings.
• Nominal Consideration: £1 — The price at which the subsidiary is being sold.
• Gross Proceeds: $10.0M — Raised through registered direct offering and concurrent private placement.

Frequently Asked Questions